Mometasone

證據等級: L5

預測適應症: 1 個

Mometasone: From Allergic Rhinitis & Skin Disorders to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Mometasone is a potent synthetic glucocorticoid used intranasally and topically for allergic rhinitis, asthma, nasal polyposis, and inflammatory skin conditions. The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma (CTCL), with 0 registered clinical trials and 2 case report publications currently available to support this direction — placing it at an early exploratory stage.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis, asthma, nasal polyposis, allergic skin disorders
Predicted New Indication	Primary cutaneous T-cell lymphoma (CTCL)
TxGNN Prediction Score	99.36%
Evidence Level	L4 (mechanism-based; no controlled trials)
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Mometasone is a high-potency synthetic glucocorticoid that exerts its effects by binding to the glucocorticoid receptor (GR, encoded by NR3C1). Upon activation, the GR–ligand complex translocates to the nucleus and modulates transcription of target genes. This mechanism underpins its well-established anti-inflammatory and immunosuppressive actions in allergic and inflammatory conditions.

The connection to CTCL — a malignancy of skin-resident T lymphocytes — is mechanistically plausible via at least three pathways: (1) direct pro-apoptotic signalling in malignant T cells through GR-α activation of the BIM/PUMA pathway; (2) tumour microenvironment disruption via suppression of NF-κB, IL-2, IL-4, and IL-13, which are key Th2 cytokines that sustain the neoplastic milieu; and (3) anti-proliferative effects on lymphoid cells that are characteristic of all potent glucocorticoids.

This biological rationale is not merely theoretical. NCCN guidelines already list Class I–II topical corticosteroids as a standard treatment option for early-stage Mycosis Fungoides (MF, the most common CTCL subtype, accounting for ~75% of cases) at stages IA–IIA. Mometasone, a Class II corticosteroid, falls squarely within this recommended class. The existing clinical gap is that most supporting evidence has been generated with Class I agents (e.g., clobetasol propionate), and mometasone-specific CTCL data remain sparse. The TxGNN knowledge graph prediction likely surfaces this connection by recognising the shared GR-mediated pharmacology.

Clinical Trial Evidence

Currently no related clinical trials registered for Mometasone in primary cutaneous T-cell lymphoma.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25442255	2015	Case Report	Journal of Cutaneous Pathology	Reports an 11-year-old boy with a 7-year history of CD8⁺CD56⁺ cytotoxic-phenotype Mycosis Fungoides; illustrates challenges in paediatric CTCL diagnosis and documents corticosteroid use as part of clinical management
40821495	2025	Case Report	Proceedings (Baylor University Medical Center)	Reports a 62-year-old woman with refractory cutaneous pseudolymphoma; mometasone was used unsuccessfully prior to escalation to tapinarof, indirectly demonstrating mometasone’s involvement in cutaneous lymphoproliferative management

India Market Information

Mometasone currently has no registered products in India (0 approvals on record). This drug is classified as not marketed in India under the available regulatory data.

Safety Considerations

Drug-Target Interaction (Pharmacology): Mometasone is a synthetic glucocorticoid that acts as a ligand at the Glucocorticoid Receptor (GR / NR3C1, Entrez Gene: 2908). Marketed formulations include:

Nasonex® (intranasal, for allergic rhinitis and nasal polyposis)
Elocon® (topical, for inflammatory skin disorders)
Enerzair® Breezhaler® (QVM149, fixed-dose combination with indacaterol/glycopyrronium, for uncontrolled asthma — completed Phase 3)

Please refer to the package insert for complete warnings, contraindications, and safety information, as these data were not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for mometasone in CTCL is biologically coherent and grounded in NCCN-recognised clinical practice for early MF, but the current evidence pack contains only 2 case reports — neither of which was a designed CTCL treatment study — and zero registered clinical trials. This is insufficient to advance beyond a research question stage.

To proceed, the following is needed:

Regulatory safety data: Retrieve the full prescribing information (package insert) from the TFDA or CDSCO to complete the S1 safety screening — currently a blocking data gap
Systematic literature review: Conduct a structured PubMed/Embase search specifically for mometasone or class II topical corticosteroids in Mycosis Fungoides/CTCL to capture any evidence missed by the current query
MOA gap closure: Query DrugBank API for complete pharmacology data including binding affinity, selectivity versus other steroid receptors (MR, AR, PR), and any reported GR-mediated apoptosis data in lymphoid cells
Benchmark against class I steroids: Identify published efficacy data for clobetasol in CTCL as a comparator to estimate the potential relative efficacy of mometasone (Class II)
Feasibility assessment for investigator-initiated trial: Given the existing NCCN framework, a small prospective observational study or retrospective chart review at a dermatology-oncology centre may be achievable as a first step before formal trial registration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.